Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies

Jennifer G Goldman*, Christopher G. Goetz, Melanie Brandabur, Michelle Sanfilippo, Glenn T. Stebbins

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

81 Scopus citations


Dopaminergic treatment in dementia with Lewy bodies (DLB) requires balancing risk of worsened psychosis and potential motor benefit. We assessed the effects of increased dopaminergic medication on psychosis and motor function in DLB. We studied 19 subjects fulfilling probable DLB Consensus criteria before and after increased dopaminergic medications. Standard clinical measures included: Thought Disorder score from the Unified Parkinson's disease Rating Scale (UPDRS) Part I, total motor score (UPDRS Part III), and Hoehn-Yahr (H&Y) stage. Motor benefit defined as >10% improvement over baseline UPDRS Part III score, occurred in only one-third of subjects. In this group, worsened hallucinations or psychosis developed in one-third. Considering motor benefit without exacerbation of psychosis as our aim, only 4 DLB subjects (22%) achieved this goal. Our results suggest that dopaminergic medications have limited benefit in DLB because of the low likelihood of motor improvement and the risk of psychosis exacerbation.

Original languageEnglish (US)
Pages (from-to)2248-2250
Number of pages3
JournalMovement Disorders
Issue number15
StatePublished - Nov 15 2008


  • Dementia with Lewy bodies
  • Levodopa
  • Parkinsonism
  • Psychosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies'. Together they form a unique fingerprint.

Cite this